How does 177A's PE Ratio compare to its peers?

177A is good value based on its Price-To-Earnings Ratio (23.4x) compared to the peer average (45.3x).

How does 177A's PE Ratio compare vs other companies in the Asian Biotechs Industry?

177A is good value based on its Price-To-Earnings Ratio (23.4x) compared to the Asian Biotechs industry average (29.8x).

What is 177A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

177A is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).

What is the Fair Price of 177A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

177A (¥1760) is trading above our estimate of [[fair value]] (¥329.07)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

177A Stock Overview

Manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. More details

177A fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 25.75% per year

Revenue grew by 0.6% over the past year

Risk Analysis

Profit margins (8.1%) are lower than last year (17.5%)

Does not have a meaningful market cap (¥9B)

My Notes

Capture your thoughts, links and company narrative

Kohjin Bio Co., Ltd. Competitors

Pharma Foods International

TSE:2929

JP¥26.0b

Takara Bio

TSE:4974

JP¥119.5b

GNI Group

TSE:2160

JP¥161.1b

PeptiDream

TSE:4587

JP¥333.1b

Price History & Performance

Summary of share price highs, lows and changes for Kohjin Bio
Historical stock prices
Current Share Price	JP¥1,760.00
52 Week High	JP¥3,065.00
52 Week Low	JP¥1,281.00
Beta	0
1 Month Change	0.86%
3 Month Change	-7.81%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-25.74%

Recent updates

Shareholder Returns

	177A	JP Biotechs	JP Market
7D	4.8%	-1.7%	-1.5%
1Y	n/a	18.5%	13.7%

Return vs Industry: Insufficient data to determine how 177A performed against the JP Biotechs industry.

Return vs Market: Insufficient data to determine how 177A performed against the JP Market.

Price Volatility

Is 177A's price volatile compared to industry and market?
177A volatility
177A Average Weekly Movement	3.6%
Biotechs Industry Average Movement	6.9%
Market Average Movement	3.6%
10% most volatile stocks in JP Market	7.3%
10% least volatile stocks in JP Market	1.9%

Stable Share Price: 177A has not had significant price volatility in the past 3 months compared to the JP market.

Volatility Over Time: 177A's weekly volatility has decreased from 10% to 4% over the past year.

About the Company

Founded	Employees	CEO	Website
1981	159	Takahito Nakamura	www.kohjin-bio.jp

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums.

Kohjin Bio Co., Ltd. Fundamentals Summary

How do Kohjin Bio's earnings and revenue compare to its market cap?
177A fundamental statistics
Market cap	JP¥9.00b
Earnings (TTM)	JP¥384.00m
Revenue (TTM)	JP¥4.77b

23.4x

P/E Ratio

1.9x

P/S Ratio

Is 177A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
177A income statement (TTM)
Revenue	JP¥4.77b
Cost of Revenue	JP¥2.89b
Gross Profit	JP¥1.88b
Other Expenses	JP¥1.50b
Earnings	JP¥384.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	75.12
Gross Margin	39.43%
Net Profit Margin	8.05%
Debt/Equity Ratio	65.1%

How did 177A perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

15%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 10:37
End of Day Share Price	2024/12/20 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kohjin Bio Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kyoichiro Shigemura	Nomura Securities Co. Ltd.